

---

Research article

# In vitro and in vivo evaluation of human adenovirus type 49 as a vector for therapeutic applications

Emily A. Bates<sup>1\*</sup>, John R. Counsell<sup>2,3\*</sup>, Sophie Alizert<sup>4</sup>, Alexander T. Baker<sup>1,5</sup>, Natalie Suff<sup>6,7</sup>, Angela C. Bradshaw<sup>4</sup>, Simon N. Waddington<sup>7,8</sup>, Stuart A. Nicklin<sup>4</sup>, Andrew H. Baker<sup>4,9\*</sup> and Alan L. Parker<sup>1\*</sup>

- <sup>1</sup> Division of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, CF14 4XN, UK  
<sup>2</sup> Genetics and Genomic Medicine Research and Teaching Department, UCL Great Ormond Street Institute of Child Health, London, WC1N 1EH, UK  
<sup>3</sup> NIHR Great Ormond Street Hospital Biomedical Research Centre, 30 Guilford Street, London, WC1N 1EH, UK  
<sup>4</sup> Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, G12 8TA, UK  
<sup>5</sup> Center for Individualized Medicine, Mayo Clinic, Scottsdale, Arizona, USA  
<sup>6</sup> Gene Transfer Technology Group, Institute for Women's Health, University College London, 86-96 Chenies Mews, London, WC1E 6BT, UK  
<sup>7</sup> Department of Women and Children's Health, King's College London, St Thomas' Hospital, Westminster Bridge Road, London, SE1 7EH.  
<sup>8</sup> MRC Antiviral Gene Therapy Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa  
<sup>9</sup> University of Edinburgh, Queen's Medical Research Institute, 47 Little France Crescent, Edinburgh, EH16 4TJ, UK  
\* Contributed equally to this manuscript.  
\* Correspondence: [andy.baker@ed.ac.uk](mailto:andy.baker@ed.ac.uk); [ParkerAL@cardiff.ac.uk](mailto:ParkerAL@cardiff.ac.uk)

**Abstract:** The human adenovirus phylogenetic tree is split across seven species (A-G). Species D adenoviruses offer potential advantages for gene therapy applications, with low rates of preexisting immunity detected across screened populations. However, many aspects of the basic virology of species D, such as their cellular tropism, receptor usage and *in vivo* biodistribution profile, remain unknown. Here, we have characterized human adenovirus type 49 (HAdV-D49), a relatively understudied species D member. We report that HAdV-D49 does not appear to use a single pathway to gain cell entry but appears able to interact with various surface molecules for entry. As such, HAdV-D49 can transduce a broad range of cell types *in vitro*, with variable engagement of blood coagulation FX. Interestingly, when comparing *in vivo* biodistribution to adenovirus type 5, HAdV-D49 vectors show reduced liver targeting whilst maintaining transduction of lung and spleen. Overall, this presents HAdV-D49 as a robust viral vector platform for *ex vivo* manipulation of human cells and for *in vivo* applications where the therapeutic goal is to target the lung or gain access to immune cells in the spleen whilst avoiding liver interactions, such as intravascular vaccine applications.

**Keywords:** Adenovirus; viral vector; gene therapy, vaccines.

---

## 1. Introduction

Human adenoviruses are non-enveloped, icosahedral viruses, divided across seven species (A-G) [1]. They have emerged as popular gene therapy vectors for therapeutic purposes, where they can be grown to high titers and efficiently transduce a range of cell types *in vivo* and *in vitro* [2]. Their diverse genetic background enables flexibility when selecting capsid serotypes with unique cell targeting profiles and host interaction characteristics, depending on the therapeutic goal of gene transfer.

Adenoviruses have been used clinically for gene supplementation, vaccination, and as oncolytic virotherapies [3]. To date, there have been over 100 adenovirus types described (<http://hadvwg.gmu.edu/>). When selecting an adenoviral vector for *in vivo* gene therapy applications, it is advantageous to select a viral platform with low levels of

seroprevalence in the population. Such preexisting immunity would otherwise hamper the efficacy of adenovirus vectors, due to rapid neutralization by the reticuloendothelial system. This is particularly relevant to species C adenoviruses, such as human adenovirus type 5 (HAdV-C5), for which neutralizing antibodies have been detected at rates of 30-90% in human populations [4,5].

Several groups have attempted to circumvent this restriction by selecting adenovirus capsids with naturally low seroprevalence rates, such as the chimpanzee adenovirus platform developed by The Jenner Institute for vaccination against SARS-CoV2 [6,7]. However, it has been reported that some populations do harbor preexisting immunity to chimpanzee adenoviruses, as observed in a Chinese cohort [8]. Further attempts to mitigate preexisting immunity against adenoviruses has focused on those derived from species B or D, due to their comparative rarity in human populations [4,9,10]. This includes the species D member HAdV-D26, which is the basis of the Janssen Pharmaceuticals vaccine against SARS-CoV2 [11] and the species B variant Enadenotucirev (ColoAd1), which was developed by directed evolution of a panel of different adenovirus strains [12].

Adenovirus type 49 (HAdV-D49) is a species D member, which has also been evaluated for potential for gene therapy applications *in vitro* and *ex vivo*, owing to its particularly low seroprevalence rates. A study of a Scottish cohort failed to detect any neutralizing antibodies to HAdV-D49 at all [5], although low levels of 1-2% were detected in further screening studies in Europe [13,14]. Previous studies have highlighted Ad49 as a potential vaccine vector [15] and as an effective agent for *ex vivo* cardiovascular gene delivery vector due to its efficiency in rapidly transducing endothelial and vascular smooth muscle cells [5]. Previous studies into the basic virology of HAdV-D49 suggest that HAdV-D49 may engage CD46 as a cellular receptor [15], although its exact entry mechanism remains to be elucidated. Overall, there remains limited investigations into the basic biology of HAdV-D49 and its human cell transduction characteristics, despite its described advantages.

Here we have evaluated the transduction characteristics of HAdV-D49 for *in vitro* and *in vivo* manipulation of cells, to better evaluate its potential use and therapeutic exploitation.

## 2. Materials and Methods

**Cells and tissues:** HEK 293T cells (human embryonic kidney: ATCC CRL-1573) were used for viral production, cultured in Dulbecco's modified Eagle's medium (DMEM; Invitrogen) supplemented with 2mM L-glutamine (Invitrogen) and 10% fetal bovine serum (FBS; PAA Laboratories). HepG2 (hepatocellular carcinoma: ATCC HB-8065), A549 (human lung carcinoma: ATCC CCL-185), SKOV3 (human ovarian carcinoma: ATCC HTB-77) cells, HeLa (cervical adenocarcinoma cells: ATCC CCL-2), HT-29 (colon adenocarcinoma cells: ATCC HTB-38) and MDA435 (melanocyte: ATCC HTB-129) were cultured in DMEM, minimal essential medium (MEM) or RPMI-1640 medium (Invitrogen with 2mM L-glutamine, 10% FCS, and 1mM sodium pyruvate (Sigma-Aldrich). Cells were maintained at 37°C and 5% CO<sub>2</sub>.

**Adenovirus culture:** HAdV-C5 and HAdV-D49 are replication incompetent E1/E3 deleted vectors constructed as described previously [14]. HAdV-C5/49 fiber (49F) and fiber knob (49K) pseudotypes and HVR mutant versions were generated using previously described recombineering methods [23]. Viruses were propagated in HEK 293T, E1-complementing cell lines and purified using CsCl gradients. Viral recovery was quantified by micro-BCA assay (ThermoFisher) assuming that 1g protein = 4 x 10<sup>9</sup> viral particles (vp) and confirmed by nanosight measurement (Nanosight). Infectious units (pfu) were quantified by end-point dilution plaque assay.

**Luciferase transduction assay:** Performed using a commercially available luciferase assay kit (Promega). Cells were seeded into 96-well cell plates at a density of 2x10<sup>4</sup> cells/well in 200µl of cell culture media and left to adhere overnight. Viruses were

administered in relevant media and incubated for 3-hours, before replenishing with complete media and culturing for a further 45-hours. Cells were then lysed, with lysates assayed for luciferase activity according to kit manufacturer's instructions. Luciferase activity was measured in relative light units (RLU) using a plate reader (Clariostar, BMG Labtech). Total protein concentration was determined in the lysate using the Pierce BCA protein assay kit (Thermofisher) according to the manufacturer's protocol. Transduction efficiency was expressed as RLU/mg of lysate protein.

**Heparinase and Neuraminidase transduction assay:** Cells were seeded at a density of  $5 \times 10^4$  cells/well in 96-well plates. Neuraminidase (from Vibrio Cholera, Merck) was added at a concentration of 50mU/ml, whilst Heparinase III (from Flavobacterium heparinum, Merck) was added at a concentration of 1U/ml, diluted in serum free media. Adenoviruses carrying a luciferase transgene were added in serum free media and incubated on ice for 1-hour. Cells were then washed with cold PBS and replenished with complete media, before returning to incubation at 37°C for 48-hours. Cells were analyzed for luciferase activity as described above.

**Hemagglutination assay:** Erythrocytes were extracted from blood cells derived from a human donor, who gave informed consent. 50 $\mu$ l of 1% erythrocyte suspension was layered in each well of a 96-well plate, before adding 50 $\mu$ l of relevant virus ( $1 \times 10^9$  VP) and gently mixing into the erythrocyte suspension. Hemagglutination was assessed visually.

**Generation of recombinant fiber knob proteins:** Recombinant fiber knob proteins were produced as described previously [16]. pQE-30 vectors containing the coding sequence spanning 13 amino acids upstream of the TLW motif to the stop codon, were transformed into SG13009 competent cells harboring the pREP-4 plasmid. 1L of bacterial cells were grown to OD0.6 and protein expression induced with a final concentration of 0.5mM IPTG. Cells were pelleted by centrifugation and resuspended in 50ml 383 lysis buffer (50 mM Tris, pH 8.0, 300 mM NaCl, 1% (v/v) NP40, 1 mg/ml Lysozyme, 1 mM  $\beta$ -mercaptoethanol). Cell lysate was then loaded to a HisTrap FF Crude column and eluted by imidazole. Fractions determined to contain protein of interest were then concentrated to <1ml total volume and purified by size exclusion chromatography using a Superdex 200 10/300 GL Increase column.

**Blocking of virus infection with recombinant fiber knob protein:** Cells were seeded in 96-well plates at a density of  $2 \times 10^4$  cells/well. The relevant adenovirus fiber knob was added to wells in 200 $\mu$ l of cold PBS and incubated at 4°C for 1-hour. Media was then removed and adenovirus vectors containing luciferase payload were introduced at the required dose in culture media before incubating at 4°C for 1-hour. Media was then removed, replaced with complete media and cells incubated 37°C for 48-hours. Transduction efficiency was measured by luciferase assay, as described above.

**Animals:** For *in vivo* studies, animal procedures were performed in strict accordance with UK Home Office guidelines. These studies were approved by the University of Glasgow Animal Procedures and Ethics Committee and performed under UK Home Office license PPL 60/4429 or by the ethical review committee of University College London under UK Home Office License PPL 70/6014. All efforts were made to minimize suffering.

For intravenous studies, outbred CD1 mice (Charles River), were injected intravenously with the stated doses of adenoviral vectors and blinded during the course of *in vivo* investigations. Fetal intracranial injection was performed as previously described [17,18]. Briefly, pregnant mice carrying pups at 16 days of gestation were anesthetized using isoflurane inhalation anesthesia and a midline laparotomy was performed to expose the uterus. Five microliters of vector was administered to each fetus via a transuterine injection targeting the anterior horn of the lateral ventricle of the left hemisphere of the brain. The laparotomy was sutured and mice were provided topical and systemic analgesia and allowed to recover in a warm chamber.

**In vivo bioluminescent imaging:** Images and bioluminescence data were gathered as described previously [19]. Firefly D-luciferin (150 mg/kg) was administered to mice by intraperitoneal injection 5-minutes before imaging with a cooled charge-coupled device (CCD) camera (IVIS Lumina II, PerkinElmer). Detection of bioluminescence in visceral organs was performed using the auto region of interest (ROI) quantification function in Living Image 4.4 (PerkinElmer). Signal intensities were expressed as photons per second per centimeter<sup>2</sup> per steradian.

**Calculation of vector genome copies in mouse organs:** Genomic DNA was extracted from the organ of interest following tissue harvest after termination of *in vivo* experiments. DNA was extracted from tissue using the Qiagen DNeasy blood and tissue kit. Vector genome copies were quantified by qPCR, targeted to the adenoviral vector genome and expressed per 50 ng of extracted DNA.

**Statistical analysis:** Data presented are derived from a minimum of two experimental replicates per group, unless otherwise stated. Transduction graphs are displayed with a log scale and for these experiments data were log transformed before analysis. Statistical significance was calculated using ANOVA or Student's t-test;  $p < 0.05$  was considered statistically significant.


### 3. Results

Our experiments focused on the *in vitro* and *in vivo* transduction characteristics of HAdV-D49 vectors with relevance to gene therapy applications.

#### 3.1. HAdV-D49 transduces of a broad range of cell types *in vitro*.

We initially profiled the transduction efficiency of HAdV-D49 in a range of cell types to gauge its potential use for cellular gene transfer *in vitro*. Expression of a luciferase highlighted efficient transduction of several immortalized cell types, including alveolar basal endothelial cells (A549 cells), hepatocytes (HepG2s), colon adenocarcinoma cells (HT29), cervical adenocarcinoma cells (HeLa), melanocytes (MDA435) and ovarian carcinoma cells (SKOV3). In the majority of cases, HAdV-D49 demonstrated a significantly increased transduction efficiency compared to HAdV-C5 (Figure 1A).

In light of the above findings, we investigated whether FX binding could further enhance HAdV-D49 mediated transduction. A previous study indicated that HAdV-D49 forms an unstable complex with FX [20], and therefore it remained unclear how this unstable complex might impact on cellular transduction efficiency. Cells were transduced with either HAdV-D49 or HAdV-C5 vectors expressing luciferase in serum-free media in the presence or absence of 10 $\mu$ g/ml FX, with expression determined by bioluminescent signal from the luciferase transgene (Figure 1B). HAdV-D49 transduction was only significantly increased by the presence of FX in MDA 435 cells although. FX consistently enhanced transduction of HAdV-C5 with a significant increase for three cell lines (A549, MDA 435 and SKOV3). We therefore suggest FX plays a variable role in HAdV-D49 infection; however, presence of FX is not a requirement for cell entry, and nor does it's presence enhance transduction mediated by HAdV-D49 in all cell lines tested.




**Figure 1.** Profiling of HAdV-D49 transduction in cancer cell lines *in vitro*. Transduction of HAdV-C5 (shown as Ad5) and HAdV-D49 (shown as Ad49) in A549, Hela, HepG2, HT20, MDA 435 and Skov3 cell lines at (A) 1000 vp/cell and (B) 10 000 vp/cell. Luciferase expression was measured 48 hours post infection. (C) Transduction of same cell lines either in presence or absence of recombinant FX.

### 3.2. *In vivo* biodistribution profiling shows FX interaction does not confer increased liver targeting.

We next investigated the *in vivo* biodistribution of HAdV-D49 vectors in mice, to determine which visceral organs were targeted by systemic delivery. We delivered HAdV-D49 vectors carrying a luciferase transgene to mice via intravenous injection and quantified vector genome copy numbers and luciferase expression in a range of target organs 48-hours later, comparing their distribution to HAdV-C5 (Figure 2). As expected, HAdV-C5 vectors showed strong liver tropism (Figure 2A). Despite a possible interaction with FX, HAdV-D49 did not appear to transduce the liver (Figure 2B) but instead demonstrated increased uptake in the spleen (Figure 2C). Quantification of vector genomes recovered from the lung, liver, spleen, heart, kidney and pancreas support these

findings (Figure 2D). HAdV-D49 shows highest uptake in the lung and spleen with significantly lower uptake in the liver compared to HAdV-C5. We then considered the effect of significantly higher levels of HAdV-D49 in the spleen on cytokine production. Evaluation of cytokine profiles from mouse plasma shows that HAdV-D49 treatment significantly increases a panel of inflammatory cytokines, including FGF, MCP1, MIG, IFN-gamma, IL1-beta, IL-2, IL-5, IL-6, IL-12 and IP-10. Increased cytokine activation coupled with reduced liver targeting suggests that HAdV-D49 might possess advantages over HAdV-C5 for use in gene therapy or vaccine applications.




**Figure 2.** *In vivo* biodistribution analysis of HAdV-D49 vectors compared to HAdV-C5 vectors. IVIS imaging system used for *in vivo* quantification of (A) HAdV-C5 (shown as Ad5) liver transduction with PBS control; (B) IVIS images of HAdV-D49 (shown as Ad49) transduction with mice imaged on their backs, and (C) IVIS images HAdV-D49 (Ad49) transduction when mice are imaged on their side. (D) Quantification of biodistribution using qPCR to evaluate vector genomes in lung, liver, spleen, heart, kidney and pancreas. (E) Cytokine analysis in mouse plasma after HAdV-C5 (Ad5) or HAdV-D49 (Ad49) injection demonstrated as fold increase of HAdV-D49 in comparison to HAdV-C5.

### 3.3. HAdV-D49 fiber alone does not mediate liver transduction *in vivo*.

To further dissect the mechanistic basis of the decreased hepatic transduction and increased splenic transduction observed following intravascular administration of HAdV-D49 compared to HAdV-C5, we utilised a panel of HAdV-C5/49 pseudotyped vectors. To assess whether this altered distribution results from the interaction between the HAdV-D49 primary receptors and the fiber knob protein, we developed HAdV-C5 vectors pseudotyped with either the fiber knob protein alone from HAdV-D49 (HAdV-C5/K49) or the whole fiber (HAdV-C5/F49). Since hepatic transduction of HAdV-C5 is known to be mediated by the high affinity interaction between the HAdV-C5 hexon protein and FX, we also generated mutants with substitutions of critical FX binding residues in HVR7 to abrogate FX binding and thus limit liver transduction. As expected, HAdV-C5 vectors with a wt hexon showed higher transduction of the liver compared to those with ablation of the FX binding (HVR mutant). Interestingly, when the whole


HAdV-C5 fiber was replaced by HAdV-D49 whole fiber, no uptake in the liver was observed for either the wt hexon and HVR mutant. However, liver transduction was restored when only the HAdV-D49 fiber knob was swapped. No liver transduction was observed in HAdV-C5/K49 when HVR was mutated. This indicates that the fiber alone appears not to be mediating splenic transduction and HAdV-D49 most likely requires additional components, beyond its fiber, to define its tropism *in vivo*. In addition, this data suggests HAdV-D49 fiber knob does not significantly alter HAdV-C5 biodistribution when administered intravenously and is able to mediate transduction in the liver.



**Figure 4.** Evaluation of the HAdV-D49 fiber and fiber knob *in vivo*. Transduction of HAdV-C5 and HAdV-C5/49 fiber (F49) and fiber knob (49K) pseudotypes *in vivo* with and without the hexon mutation (HVR mutant) to reduce liver uptake.

### 3.4 HAdV-D49 show similar levels of intracranial transduction to HAdV-C5.

In order to evaluate the potential of HAdV-D49 as a platform for neurological gene transfer applications, MF1 mice were injected intracranially *in utero* with  $1 \times 10^9$  vp of either HAdV-C5 or HAdV-D49 expressing luciferase. At three months of age, mice were IVIS imaged for luciferase activity (Figure 3). Although mice treated with HAdV-D49.Luc mediated readily detectable levels of transduction of the brain, the levels achieved were lower than with HAdV-C5,



**Figure 3.** In vivo bioluminescence imaging of luciferase expression mediated by HAdV-C5 (Ad5) vectors compared to HAdV-D49 (Ad49) vectors after fetal intracranial injection. IVIS imaging system was performed at three months of age.


### 3.5. HAdV-D49 infection of target cells does not appear to be attributed to a single cell surface marker.

We have demonstrated HAdV-D49 exhibits a broad tropism both *in vitro* and *in vivo*, we therefore aimed to further our understanding of the mechanism underpinning HAdV-D49 receptor usage. We initially investigated the extent to which HAdV-D49 can engage CAR for transduction of hepatocytes (HepG2). For these studies, CAR binding was

blocked using recombinant HAdV-C5 knob protein prior to transduction (Figure 5A). As expected, HAdV-C5 knob treatment clearly blocked transduction mediated by HAdV-C5, however the same treatment had no effect on HAdV-D49 transduction. In addition, recombinant HAdV-D49 knob was also used to block cellular receptors. Interestingly, recombinant HAdV-D49 knob was able to inhibit transduction mediated by HAdV-C5, indicating that HAdV-D49 knob protein can bind and block CAR albeit less efficiently than recombinant HAdV-C5. Interestingly, recombinant HAdV-D49 knob protein was not able to inhibit HAdV-D49 mediated cell infectivity, except poorly at the highest concentration. This indicates that HAdV-D49 may not be solely dependent on binding of its fiber knob protein to cells for transduction of cells, and that other capsid proteins may be critical.

We observed HAdV-D49 hemagglutinates human serum at high concentrations ( $10^9$  vp/well), indicating it may bind to CAR or sialic acid, like other species D adenoviruses [21] (Figure 5B). We investigated this potential targeting of sialic acid as well as heparan sulfate proteoglycans (HSPGs), given that these have been identified as interacting partners for adenovirus transduction [21–26]. To probe this, hepatocytes (HepG2 cells were transduced in the presence or absence of neuraminidase and heparinase to inhibit sialic acid and HSPGs, respectively. However, neither treatment appeared to significantly diminish HAdV-D49 transduction, indicating that neither is essential for transduction (Figure 5C-D).

Finally, we investigated CD46 interaction as it has previously been described as a potential involvement in HAdV-D49 infection [15, 23]. CD46 was blocked on A549, Hela and SKOV3 cells using a specific monoclonal antibody (MEM-258) prior to transduction with HAdV-C5, HAdV-D49 and HAdV-B35. HAdV-D49 infection was reduced significantly in all three cell lines when CD46 was blocked. HAdV-B35 saw a decrease in transduction for all three cell lines whereas blocking CD46 had a minimal effect on HAdV-C5 infection. This data suggests CD46 is a possible receptor for HAdV-D49 agreeing with the previous data however it is not likely to be the sole receptor as HAdV-D49 remains able to readily transduce cells when CD46 is blocked.



**Figure 5.** HAdV-D49 can interact with multiple receptors to transduce target cells. (A) Blocking of HAdV-C5 (Ad5) and HAdV-D49 (Ad49) transduction in hepatocytes (HepG2) with dilution of HAdV-C5 or HAdV-D49 fiber knob (100 $\mu\text{g}$  – 0.001 $\mu\text{g}$  /10<sup>5</sup> cells). (B) Hemagglutination profiling of several serotypes including HAdV-C5 and HAdV-D49. HAdV-C5 and HAdV-D49 transduction in hepatocytes after treatment with (C) heparinase and (D) neuraminidase. (E) Transduction of HAdV-C5, HAdV-D49 and HAdV-B35 (Ad35) in A549, HeLa and SKOV3 cells following blocking with 258-MEM, anti-CD46 antibody.

#### 4. Discussion

Adenoviruses have been widely used in gene therapy for a variety of applications, owing to their diversity and efficiency in delivering therapeutic DNA cassettes to the nucleus of cells *in vitro* and *in vivo*. Common applications of adenoviruses include oncolytic virotherapies [1], *ex vivo* cell manipulation [5] and vaccine delivery [7,11,27,28], whilst recently they have been used preclinically to mediate *in utero* gene editing of disease-causing mutations in fetal mice [29]. Clinical translation of adenovirus therapies could be accelerated by greater understanding of their biology and interactions with human proteins. Additionally, many of the current adenovirus platforms are restricted by prevalence of neutralizing antibodies against adenoviral capsid proteins, which restrict their delivery to the desired cell types *in vivo*.

Here we have shown that HAdV-D49 vectors can be used to deliver genes to a wide range of target cells both *in vitro* and *in vivo*. We identified that HAdV-D49 showed enhanced transduction of hepatocytes *in vitro* in the presence of human serum, which was linked to a potential interaction with human FX. Given previous reports of HAdV-C5 utilizing FX as a partner for enhanced interaction with its CAR receptor [20,30], we expected a similar concept for HAdV-D49, although this was not an absolute requirement. Furthermore, the fiber knob domain of HAdV-D49 did not block HAdV-D49 entry into hepatocytes, suggesting that further interacting partners may be involved. This reaffirms the apparent complexity of HAdV-D49 tropism and interactions with human cells during transduction.

Evaluation of HAdV-D49 biodistribution was efficient in mediating gene transfer predominantly to the spleen *in vivo*, with surprisingly low levels of vector genomes detected in the liver of treated mice considering the potential for FX engagement. The high uptake of HAdV-D49 by the spleen correlated to an increase in inflammatory cytokine release. Overall, this indicates that HAdV-D49 is a versatile vector with potential usage for a range of *in vivo* and *ex vivo* gene therapy and vaccine applications.

We extended our studies deeper into the basic biology of HAdV-D49 vectors, by probing the potential mechanism for its transduction of target cells. Previous studies have suggested that HAdV-D49 utilizes CD46 as its primary cellular receptor [15]. Our data suggest that, although CD46 is interacted, it is not the exclusive receptor. A recent study describes a number of species D serotypes that are able to engage CD46 directly via the hexon [30]. Although this has not yet been described for HAdV-D49 this should be considered as a mechanism for CD46 interaction. Furthermore, we did not see evidence of a single cell adhesion molecule being absolutely required for HAdV-D49 transduction, instead identifying multiple interacting partners that may be utilized for cell entry. Evidence of potential interactions with CAR, CD46, sialic acid and FX were all evident in our data, but no single factor was deemed to be necessary and sufficient for transduction. The broad transduction profile of HAdV-D49 is therefore potentially explained by its apparent promiscuous interaction profile, maintaining efficient transduction across a range of cell types by establishing a repertoire of interaction mechanisms, for greater flexibility over other adenovirus types.

A particularly intriguing aspect of our study was the paradoxical cell tropism of HAdV-D49 *in vitro* versus *in vivo*, where it showed efficient transduction of many cell types *in vitro*, including liver cells, whereas *in vivo* its biodistribution was largely restricted to lung and spleen, with minimal transduction of liver compared to HAdV-C5. Given that all *in vitro* studies were conducted in human cells in the presence of human serum or human FX protein, it is reasonable to conclude that efficient HAdV-D49 transduction shows species dependency in its interactions with cell receptors and co-receptors. In order to maximize HAdV-D49 utilization in *in vivo* gene therapy applications, further work should be aimed at interrogating the species requirements of its cellular interactions, to identify the crucial determinants for entry. Indeed, in the context of *ex vivo* gene therapy, HAdV-D49 clearly shows promise as a versatile and robust gene transfer agent with exciting potential in preclinical and clinical applications.

**Author Contributions:** Conceptualization, A.L.P. and A.H.B.; methodology, E.A.B, A.C.B., S.N.W., S.A.N., A.L.P. and A.H.B.; investigation, E.A.B, J.R.C, S.A, A.T.B, N.S, A.C.B, S.N.W, S.A.N and A.L.P; data curation, E.A.B, J.R.C, S.N.W, A.H.B and A.L.P; formal analysis, E.A.B, J.R.C., A.C.B., S.N.W., S.A.N., A.L.P. and A.H.B.; writing—original draft preparation, E.A.B, J.R.C, A.H.B and A.L.P; writing—review and editing, S.A, A.T.B, A.C.B, S.N.W, S.A.N, A.L.P. and A.H.B.; funding acquisition, S.N.W, A.H.B and A.L.P. All authors have read and agreed to the published version of the manuscript.

**Funding:** EAB is supported by a Cardiff University School of Medicine PhD studentship AC1170AP02 (to ALP) and by Cancer Research UK Experimental Cancer Medicine Centre funding (C7838/A25173). JRC received funding from NIHR GOSH BRC grant 17BX23. ATB was funded by a Tenovus Cancer Care Ph.D. studentship (reference PhD2015/L13) to ALP. ACB was supported by a Personal Research Fellowship from the Royal Society of Edinburgh (RSE/33457). NS received funding from the Wellbeing of Women Research training fellowship grant RT414 and the Priory foundation and Action Medical Research grant GN2647. ALP received funding from Cancer Research UK (C52915/A29104).

**Institutional Review Board Statement:** All in vivo animal studies were performed in strict accordance with UK Home Office guidelines under University of Glasgow Animal Procedures and Ethics Committee and performed under UK Home Office license PPL 60/4429, or under UK Home Office regulations and approved by the ethical review committee of University College London under UK Home Office License PPL 70/6014. Every effort was made to minimize suffering.

**Data Availability Statement:** The datasets generated during and/or analysed during the current study are available from the corresponding authors on reasonable request.

**Acknowledgments:** We thank Nicola Britton and Gregor Aitchison for technical support.

**Conflicts of Interest:** The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

## References

1. Baker, A.T.; Aguirre-Hernández, C.; Halldén, G.; Parker, A.L. Designer Oncolytic Adenovirus: Coming of Age. *Cancers* **2018**, *10*, doi:10.3390/cancers10060201.
2. Lee, C.S.; Bishop, E.S.; Zhang, R.; Yu, X.; Farina, E.M.; Yan, S.; Zhao, C.; Zeng, Z.; Shu, Y.; Wu, X.; et al. Adenovirus-Mediated Gene Delivery: Potential Applications for Gene and Cell-Based Therapies in the New Era of Personalized Medicine. *Genes & Diseases* **2017**, *4*, 43–63, doi:https://doi.org/10.1016/j.gendis.2017.04.001.
3. Wold, W.S.M.; Toth, K. Adenovirus Vectors for Gene Therapy, Vaccination and Cancer Gene Therapy. *Current gene therapy* **2013**, *13*, 421–433, doi:10.2174/1566523213666131125095046.
4. Abbink, P.; Lemckert, A.A.C.; Ewald, B.A.; Lynch, D.M.; Denholtz, M.; Smits, S.; Holterman, L.; Damen, I.; Vogels, R.; Thorner, A.R.; et al. Comparative Seroprevalence and Immunogenicity of Six Rare Serotype Recombinant Adenovirus Vaccine Vectors from Subgroups B and D. *Journal of Virology* **2007**, *81*, 4654 LP – 4663, doi:10.1128/JVI.02696-06.
5. Dakin, R.S.; Parker, A.L.; Delles, C.; Nicklin, S.A.; Baker, A.H. Efficient Transduction of Primary Vascular Cells by the Rare Adenovirus Serotype 49 Vector. *Human gene therapy* **2015**, *26*, 312–319, doi:10.1089/hum.2015.019.
6. Dicks, M.D.J.; Spencer, A.J.; Edwards, N.J.; Wadell, G.; Bojang, K.; Gilbert, S.C.; Hill, A.V.S.; Cottingham, M.G. A Novel Chimpanzee Adenovirus Vector with Low Human Seroprevalence: Improved Systems for Vector Derivation and Comparative Immunogenicity. *PLOS ONE* **2012**, *7*, e40385.
7. Voysey, M.; Clemens, S.A.C.; Madhi, S.A.; Weckx, L.Y.; Folegatti, P.M.; Aley, P.K.; Angus, B.; Baillie, V.L.; Barnabas, S.L.; Bhorat, Q.E.; et al. Safety and Efficacy of the ChAdOx1 NCoV-19 Vaccine (AZD1222) against SARS-CoV-2: An Interim Analysis of Four Randomised Controlled Trials in Brazil, South Africa, and the UK. *The Lancet* **2021**, *397*, 99–111, doi:10.1016/S0140-6736(20)32661-1.

8. Zhao, H.; Xu, C.; Luo, X.; Wei, F.; Wang, N.; Shi, H.; Ren, X. Seroprevalence of Neutralizing Antibodies against Human Adenovirus Type-5 and Chimpanzee Adenovirus Type-68 in Cancer Patients. *Frontiers in Immunology* **2018**, *9*, 335, doi:10.3389/fimmu.2018.00335.
9. Teigler, J.E.; Iampietro, M.J.; Barouch, D.H. Vaccination with Adenovirus Serotypes 35, 26, and 48 Elicits Higher Levels of Innate Cytokine Responses than Adenovirus Serotype 5 in Rhesus Monkeys. *Journal of Virology* **2012**, *86*, 9590 LP – 9598, doi:10.1128/JVI.00740-12.
10. Weaver, E.A.; Barry, M.A. Low Seroprevalent Species D Adenovirus Vectors as Influenza Vaccines. *PLOS ONE* **2013**, *8*, e73313.
11. Sadoff, J.; Gray, G.; Vandebosch, A.; Cárdenas, V.; Shukarev, G.; Grinsztejn, B.; Goepfert, P.A.; Truyers, C.; Fennema, H.; Spiessens, B.; et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. *New England Journal of Medicine* **2021**, doi:10.1056/NEJMoa2101544.
12. Dyer, A.; Di, Y.; Calderon, H.; Illingworth, S.; Kueberuwa, G.; Tedcastle, A.; Jakeman, P.; Chia, S.L.; Brown, A.; Silva, M.A.; et al. Oncolytic Group B Adenovirus Enadenotucirev Mediates Non-Apoptotic Cell Death with Membrane Disruption and Release of Inflammatory Mediators. *Molecular therapy oncolytic* **2016**, *4*, 18–30, doi:10.1016/j.omto.2016.11.003.
13. De Jong, J.C.; Wermenbol, A.G.; Verweij-Uijterwaal, M.W.; Slaterus, K.W.; Wertheim-Van Dillen, P.; Van Doornum, G.J.J.; Khoo, S.H.; Hierholzer, J.C. Adenoviruses from Human Immunodeficiency Virus-Infected Individuals, Including Two Strains That Represent New Candidate Serotypes Ad50 and Ad51 of Species B1 and D, Respectively. *Journal of Clinical Microbiology* **1999**, *37*, 3940 LP – 3945, doi:10.1128/JCM.37.12.3940-3945.1999.
14. Vogels, R.; Zuijdgeest, D.; van Rijnsoever, R.; Hartkoorn, E.; Damen, I.; de Béthune, M.-P.; Kostense, S.; Penders, G.; Helmus, N.; Koudstaal, W.; et al. Replication-Deficient Human Adenovirus Type 35 Vectors for Gene Transfer and Vaccination: Efficient Human Cell Infection and Bypass of Preexisting Adenovirus Immunity. *Journal of Virology* **2003**, *77*, 8263 LP – 8271, doi:10.1128/JVI.77.15.8263-8271.2003.
15. Lemckert, A.A.C.; Grimbergen, J.; Smits, S.; Hartkoorn, E.; Holterman, L.; Berkhout, B.; Barouch, D.H.; Vogels, R.; Quax, P.; Goudsmit, J.; et al. Generation of a Novel Replication-Incompetent Adenoviral Vector Derived from Human Adenovirus Type 49: Manufacture on PER.C6 Cells, Tropism and Immunogenicity. *Journal of General Virology* **2006**, *87*, 2891–2899, doi:https://doi.org/10.1099/vir.0.82079-0.
16. Baker, A.T.; Greenshields-Watson, A.; Coughlan, L.; Davies, J.A.; Uusi-Kerttula, H.; Cole, D.K.; Rizkallah, P.J.; Parker, A.L. Diversity within the Adenovirus Fiber Knob Hypervariable Loops Influences Primary Receptor Interactions. *Nature Communications* **2019**, *10*, 741, doi:10.1038/s41467-019-08599-y.
17. Massaro, G.; Mattar, C.N.Z.; Wong, A.M.S.; Sirka, E.; Buckley, S.M.K.; Herbert, B.R.; Karlsson, S.; Perocheau, D.P.; Burke, D.; Heales, S.; et al. Fetal Gene Therapy for Neurodegenerative Disease of Infants. *Nat Med* **2018**, *24*, 1317–1323, doi:10.1038/s41591-018-0106-7.
18. Rahim, A.A.; Wong, A.M.; Ahmadi, S.; Hoefer, K.; Buckley, S.M.K.; Hughes, D.A.; Nathwani, A.N.; Baker, A.H.; McVey, J.H.; Cooper, J.D.; et al. In Utero Administration of Ad5 and AAV Pseudotypes to the Fetal Brain Leads to Efficient, Widespread and Long-Term Gene Expression. *Gene Ther* **2012**, *19*, 936–946, doi:10.1038/gt.2011.157.
19. Buckley, S.M.K.; Delhove, J.M.K.M.; Perocheau, D.P.; Karda, R.; Rahim, A.A.; Howe, S.J.; Ward, N.J.; Birrell, M.A.; Belvisi, M.G.; Arbuthnott, P.; et al. In Vivo Bioimaging with Tissue-Specific Transcription Factor Activated Luciferase Reporters. *Scientific Reports* **2015**, *5*, 11842, doi:10.1038/srep11842.
20. Waddington, S.N.; McVey, J.H.; Bhella, D.; Parker, A.L.; Barker, K.; Atoda, H.; Pink, R.; Buckley, S.M.K.; Greig, J.A.; Denby, L.; et al. Adenovirus Serotype 5 Hexon Mediates Liver Gene Transfer. *Cell* **2008**, *132*, 397–409, doi:https://doi.org/10.1016/j.cell.2008.01.016.
21. Baker, A.T.; Mundy, R.M.; Davies, J.A.; Rizkallah, P.J.; Parker, A.L. Human Adenovirus Type 26 Uses Sialic Acid–Bearing Glycans as a Primary Cell Entry Receptor. *Science Advances* **2019**, *5*, eaax3567, doi:10.1126/sciadv.aax3567.

22. Arnberg, N.; Edlund, K.; Kidd, A.H.; Wadell, G. Adenovirus Type 37 Uses Sialic Acid as a Cellular Receptor. *Journal of virology* **2000**, *74*, 42–48.
23. Baker, A.T.; Davies, J.A.; Bates, E.A.; Moses, E.; Mundy, R.M.; Marlow, G.; Cole, D.K.; Bliss, C.M.; Rizkallah, P.J.; Parker, A.L. The Fiber Knob Protein of Human Adenovirus Type 49 Mediates Highly Efficient and Promiscuous Infection of Cancer Cell Lines Using a Novel Cell Entry Mechanism. *Journal of Virology* **2021**, *95*, e01849-20, doi:10.1128/JVI.01849-20.
24. Dechechchi, M.C.; Tamanini, A.; Bonizzato, A.; Cabrini, G. Heparan Sulfate Glycosaminoglycans Are Involved in Adenovirus Type 5 and 2-Host Cell Interactions. *Virology* **2000**, *268*, 382–390, doi:<https://doi.org/10.1006/viro.1999.0171>.
25. Dechechchi, M.C.; Melotti, P.; Bonizzato, A.; Santacatterina, M.; Chilosì, M.; Cabrini, G. Heparan Sulfate Glycosaminoglycans Are Receptors Sufficient To Mediate the Initial Binding of Adenovirus Types 2 and 5. *Journal of Virology* **2001**, *75*, 8772 LP – 8780, doi:10.1128/JVI.75.18.8772-8780.2001.
26. Tuve, S.; Wang, H.; Jacobs, J.D.; Yumul, R.C.; Smith, D.F.; Lieber, A. Role of Cellular Heparan Sulfate Proteoglycans in Infection of Human Adenovirus Serotype 3 and 35. *PLOS Pathogens* **2008**, *4*, e1000189.
27. Zhu, F.-C.; Li, Y.-H.; Guan, X.-H.; Hou, L.-H.; Wang, W.-J.; Li, J.-X.; Wu, S.-P.; Wang, B.-S.; Wang, Z.; Wang, L.; et al. Safety, Tolerability, and Immunogenicity of a Recombinant Adenovirus Type-5 Vectored COVID-19 Vaccine: A Dose-Escalation, Open-Label, Non-Randomised, First-in-Human Trial. *The Lancet* **2020**, *395*, 1845–1854, doi:10.1016/S0140-6736(20)31208-3.
28. Logunov, D.Y.; Dolzhikova, I. V; Shcheblyakov, D. V; Tukhvatulin, A.I.; Zubkova, O. V; Dzharullaeva, A.S.; Kovyrshina, A. V; Lubenets, N.L.; Grousova, D.M.; Erokhova, A.S.; et al. Safety and Efficacy of an RAd26 and RAd5 Vector-Based Heterologous Prime-Boost COVID-19 Vaccine: An Interim Analysis of a Randomised Controlled Phase 3 Trial in Russia. *The Lancet* **2021**, *397*, 671–681, doi:10.1016/S0140-6736(21)00234-8.
29. Rossidis, A.C.; Stratigis, J.D.; Chadwick, A.C.; Hartman, H.A.; Ahn, N.J.; Li, H.; Singh, K.; Coons, B.E.; Li, L.; Lv, W.; et al. In Utero CRISPR-Mediated Therapeutic Editing of Metabolic Genes. *Nature Medicine* **2018**, *24*, 1513–1518, doi:10.1038/s41591-018-0184-6.
30. Greig, J.A.; Buckley, S.M.K.; Waddington, S.N.; Parker, A.L.; Bhella, D.; Pink, R.; Rahim, A.A.; Morita, T.; Nicklin, S.A.; McVey, J.H.; et al. Influence of Coagulation Factor X on In Vitro and In Vivo Gene Delivery by Adenovirus (Ad) 5, Ad35, and Chimeric Ad5/Ad35 Vectors. *Molecular Therapy* **2009**, *17*, 1683–1691, doi:<https://doi.org/10.1038/mt.2009.152>.